Compare INLX & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | CELU |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 34.5M |
| IPO Year | 2013 | N/A |
| Metric | INLX | CELU |
|---|---|---|
| Price | $7.65 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 1.4K | ★ 32.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,336.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.82 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.50 | $1.00 |
| 52 Week High | $15.72 | $4.35 |
| Indicator | INLX | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 44.25 |
| Support Level | $7.50 | $1.21 |
| Resistance Level | $8.29 | $1.33 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 0.00 | 9.68 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.